News & Updates

Ligelizumab improves symptoms, QoL in patients with urticaria
Ligelizumab improves symptoms, QoL in patients with urticaria
02 Mar 2022 byAudrey Abella

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

Ligelizumab improves symptoms, QoL in patients with urticaria
02 Mar 2022
Universal HCV screening in pregnancy: A step toward reducing transmission?
Universal HCV screening in pregnancy: A step toward reducing transmission?
01 Mar 2022 byRoshini Claire Anthony

Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.

Universal HCV screening in pregnancy: A step toward reducing transmission?
01 Mar 2022
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
01 Mar 2022

In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.

Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
01 Mar 2022